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L-CarnitineAbstract Background: Bronchial asthma is the most common chronic disorder in childhood, and
asthma exacerbation is an important cause of childhood morbidity and hospitalization.
Aim of the work: It was to measure serum level of L-carnitine in children with bronchial asthma
and to correlate its level with the severity of the disease.
Subjects and methods: This study included 3 groups. First group included 30 asthmatic children
in acute attack, the second group included 15 children with stable asthma, and the third group (con-
trol group) included 10 apparently healthy children of matched age and sex with patients’ groups.
The severity of the acute attack was determined according to pulmonary Score system. Serum
L-carnitine levels and peak expiratory ﬂow rate (PEFR) were estimated once in control group
and stable asthmatics and twice in children with acute attack, the ﬁrst during the attack and the
second 3 weeks after the attack.
Results: Serum L-carnitine levels were signiﬁcantly reduced in children suffering from acute asth-
matic attacks than in the stable asthmatics and controls, while there was no signiﬁcant difference
between the latter two groups. Serum L-carnitine levels were not affected by the severity of the
attack (no difference between mild and moderate attacks). On the other hand, L-carnitine levels
were signiﬁcantly reduced at the time of the acute attack than after 3 weeks of the attack.
Conclusion: According to our study, it could be concluded that L-carnitine decrease is linked to
the occurrence of attack of bronchial asthma. Accordingly, it is recommended to make further stud-
ies to ﬁnd out if there is a beneﬁcial role of carnitine intake in the prophylaxis & treatment of
attacks of bronchial asthma. The recommended studies should search for the most suitable dose
& side effects of carnitine as a potential pharmaceutical agent.
ª 2014 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis. Open access under CC BY-NC-ND license.Introduction
Bronchial asthma is the most common chronic disorder in
childhood, and asthma exacerbation is an important cause of
childhood morbidity and hospitalization and has an impact
542 E. Ramadan et al.on the social and emotional aspects of lives of children and
their families [1].
The persistence or increase of asthma symptoms over time
is accompanied by a progressive decline in lung functions [2].
The pathophysiology of persistent asthma remains poorly
understood. Even with the current therapies, the symptoms
may be incompletely controlled, or they might have little effect
on disease process [3,4]. As pharmacologic therapy may have
variable results in these asthmatic children, the search for met-
abolic or nutritional deﬁciencies contributing to the disease has
continued. In instances where metabolic or nutritional deﬁ-
ciencies are a contributing factor to ongoing inﬂammatory
processes in the bronchial tree, dietary supplementation of
these deﬁciencies may provide beneﬁt [5].
L-carnitine is a cofactor that is synthesized from amino
acids lysine and methionine and plays an essential role in the
mitochondrial oxidation of long-chain fatty acids for the gen-
eration of metabolic energy. It spares muscle glycogen, im-
proves tolerance to physical activity, and reduces muscle
fatigue [6].
L-Carnitine administration is beneﬁcial to exercise and
respiratory strength training in outpatients with stable, moder-
ate-to-severe chronic obstructive pulmonary diseases [7].
Aim of the work
It was to measure serum level of L-carnitine in children with
bronchial asthma and to correlate its level with the severity
of the disease.
Subjects and methods
This case control study was conducted on 55 asthmatic chil-
dren aged from 5–12 years collected from Allergy & Asthma
clinic, pediatric department, Benha University Hospital, and
El-Obour medical family center in the period from October
2012 to March 2013. They were divided into the following
groups: Group Ia: included 30 asthmatic children during acute
asthmatic attack, Group Ib: included the same 30 asthmatic
children 3 weeks after the acute attack, Group II: included
15 children with stable asthma and Group III: included 10
apparently healthy children matched for age and sex served
as a control group. The following conditions were excluded
from the study: Any pulmonary or chronic systemic disease
other than asthma, children with immunodeﬁciency or history
of premature birth, children with hypothyroidism, intake of
medications that may affect carnitine level (antibiotics use par-
ticularly Ampicillins and anticonvulsants like valproic acid),
recent infection (especially pneumonia), surgery or anesthesia.
An informed consent was taken from parents of the studied
children before starting this study. Asthmatic children wereTable 1 Sex distribution among the studied group.
Sex Group I Group II
No % No %
Male 19 63.3 8 53.3
Female 11 36.7 7 46.7
Total 30 100 15 100diagnosed and classiﬁed according to Global Initiative for
Asthma criteria [8]. In acute asthma attack the severity of
the acute attack was determined according to pulmonary Score
System; it was calculated with regard to breath rate according
to age, wheezing severity and sternocleidomastoid muscle
activity, which were scored between 0 and 3 each. Attack
was considered mild if the pulmonary score was 63, moderate
if it was 4–6, and severe if it was 7 or more [9].
Serum L-carnitine levels were measured in peripheral blood
samples by human L-carnitine ELISA kit (Glory science,
USA), according to manufacturer’s instructions. 3 ml of ve-
nous blood was withdrawn from each child on a plain tube,
then it was centrifuged and serum was separated and kept at
20 C until analysis. Two blood samples were collected from
children with acute attack; the ﬁrst sample was collected dur-
ing the attack and the second sample was collected three weeks
after the acute attack of the same children. One blood sample
was collected from the stable asthmatic children (Group II)
and the control group (Group III).
Peak expiratory ﬂow rate (PEFR) was measured (one of the
lung functions) by peak ﬂow meter, it is the greatest out ﬂow
obtained by forced expiration after deep inspiration with
standing child then reading was taken, repeated three times
and the greatest reading was taken [11]. PEFR was measured
once in control group, and was measured twice; the ﬁrst one
was during the acute attack and second was 3 weeks after.
Statistical analysis
The collected data were organized, tabulated and statistically
analyzed using SPSS V.16 software statistical computer pack-
age. For quantitative data, the range, mean and standard devi-
ation were calculated. The difference between two means was
statistically analyzed using the student’s (t) test. For compari-
son between more than two means, the F value of analysis of
variance (ANOVA) was calculated. Pearson’s correlation coef-
ﬁcient (r) was calculated to test the association between two
variables, for all analysis; a statistical signiﬁcance of P-va-
lue > 0.05 indicates non signiﬁcant results, P-value < 0.05
indicates signiﬁcant results, and P-value < 0.01 indicates
highly signiﬁcant results.
Results
Some demographic and clinical data of the children enrolled in
the study are shown in Tables 1 and 2 which revealed that
there was no signiﬁcant difference among the studied groups
as regards sex, age, weight, height, and BMI.
There was highly signiﬁcant positive history of passive
smoking, highly signiﬁcant positive increase of the presence
of atopic manifestations and highly signiﬁcant positive familyGroup III X2 test P value
No %
5 50.0 0.747 0.688 NS
5 50.0
10 100
Table 2 Some demographic and clinical data of the studied groups.
Variable Groups F test P value
Group I (n= 30) Group II (n= 15) Group III (n= 10)
Age in years Mean ± SD 7.8 ± 2.71 7.6 ± 2.16 7.7 ± 2.83 0.03 0.97 NS
Range 5–15 5–12 5–12
Weight in kg Mean ± SD 31.47 ± 11.03 29.87 ± 9.54 29.2 ± 11.07 0.221 0.802 NS
Range 19–60 20–54 18–48
Height in cm Mean ± SD 128.73 ± 15.58 125.47 ± 12.74 127.6 ± 16.28 0.237 0.79 NS
Range 105–160 106–148 111–152
BMI Mean ± SD 18.38 ± 2.16 18.57 ± 2.84 17.26 ± 2.24 1.043 0.36 NS
Range 15.15–24.65 15.26–24.65 14.35–20.78
Table 3 Comparison between asthmatic and control groups as regards some risk factors.
Variable Asthmatic cases Control FET P value
n % n %
Passive smoking +ve 38 84.4 2 20.0 31.17 0.001HS
ve 7 15.6 8 80.0
Total 45 100 10 100
Atopy +ve 36 80.0 0 0.0 42.9 0.001 HS
ve 9 20.0 10 100.0
Total 45 100 10 100
Family history of atopy +ve 40 88.9 0 0.0 60.8 0.001 HS
ve 5 11.1 10 100
Total 45 100 10 100
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control group as shown in Table 3.
It was evident from Table 4 that there was no signiﬁcant
difference regarding residence distribution among the studied
groups. The percentage of asthmatic from rural residence
was 53.3%, and from urban residence was 46.7%.
Serum L-carnitine level was signiﬁcantly lower in group Ia
(acute attack) and group Ib (three weeks after the acute attack)
than in the stable asthmatics and controls (p value = 0.001),
while there was no signiﬁcant difference between the latter
two groups (p value = 0.618) as shown in Table 5.
Serum L-carnitine level was not different between asthmat-
ics with mild and moderate attack (p value 0.692) (Table 6),
and was signiﬁcantly reduced during the acute attack than
3 weeks after the attack as demonstrated in Table 5.
The values of PEFR were signiﬁcantly lower in the asth-
matics presenting with acute attack and three weeks after
and those with stable asthma, in comparison with the controls
(p value 0.001). However, asthmatic children with acute attack
and children with stable course showed no signiﬁcant differ-
ence in values of PEFR (p value 0.122). There was a highlyTable 4 Residence distribution among the studied groups.
Residence Groups
GroupI Group II
n % n %
Rural 16 53.3 8 53.3
Urban 14 46.7 7 46.7
Total 30 100 15 100signiﬁcant decrease in values of PEFR in asthmatics with acute
attack than 3 weeks after the attack (P value 0.001) [7] Tables 7
and 8.
As regards correlation between L-carnitine and PEFR in
the studied groups, there was a signiﬁcant positive correlation
between L-carnitine and PEFR in groups Ia, Ib and II as
shown in Table [8].Discussion
L-Carnitine has an essential role in the transport of long-chain
fatty acids through the mitochondrial membrane in order to
ensure efﬁcient oxidation of fatty acids, it is important for acti-
vation of pulmonary surfactant synthesis [12].
The lung contains more than 40 different cell types, most of
them are involved in lipid metabolism [13].
Serum carnitine level was found to be decreased in new-
borns with respiratory distress syndrome; this was proposed
to be associated with increased consumption of carnitine in
the lung tissue for surfactant synthesis [14].X2 test P value
Group III
n %
5 50.0 0.036 0.98 NS
5 50.0
10 100
Table 5 Comparison of L carnitine levels in different studied
groups.
Group L-Carnitine (lmol/L) P value
(Range) Mean ± SD
Group Ia (23–52) 37.47 ± 9.5 0.001
Group II (43–94) 60.8 ± 16.46
Group Ia (23–52) 37.47 ± 9.5 0.001
Group III (36–113) 64.8 ± 23.25
Group II (43–94) 60.8 ± 16.46 0.618
Group III (36–113) 64.8 ± 23.25
Group Ib (28–60) 41.97 ± 9.38 0.001
Group II (43–94) 60.8 ± 16.46
Group Ib (28–60) 41.97 ± 9.38 0.001
Group III (36–113) 64.8 ± 23.25
Group Ia (23–52) 37.47 ± 9.5 0.001
Group Ib (28–60) 41.97 ± 9.38
Table 7 Comparison of PEFR(L/min) levels in different
studied groups.
Group PEFR (L/min) P value
(Range) Mean ± SD
Group Ia (60–180) 106.0 ± 33.79 0.122
Group II (80–200) 123.33 ± 36.58
Group Ia (60–180) 106.0 ± 33.79 0.001
Group III (140–250) 192.0 ± 40.5
Group II (80–200) 123.33 ± 36.58 0.008
Group III (140–250) 192.0 ± 40.5
Group Ib (80–220) 136.0 ± 42.88 0.448
Group II (80–200) 123.33 ± 36.58
Group Ib (80–220) 136.0 ± 42.88 0.001
Group III (140–250) 192.0 ± 40.5
Group Ia (60–180) 106.0 ± 33.79 0.001
Group Ib (80–220) 136.0 ± 42.88
Table 8 Correlation between L-carnitine and PEFR in the
studied group.
L-Carnitine Pearson correlation P value Signiﬁcance
Group Ia PEFR 0.723 0.013 S
Group Ib PEFR(3w later) 0.544 0.043 S
Group II PEFR 0.803 0.040 S
544 E. Ramadan et al.In our study male asthmatic patients were 60%, while fe-
male patients were 40% with male to female ratio of 3:2. It
is reported that asthma symptoms are more common and more
severe in young boys but after puberty the disease seems to be
more common and more severe in girls [15].
In this study asthmatics from rural residence were 53.3%,
and from urban residence were 46.7%, although Braun-Fahr-
lander reported that the prevalence of asthma is reduced in chil-
dren raised in rural setting than urban, which may be linked to
the presence of endotoxin in these environments [16]. This dif-
ference in our study may be due to rapid urbanization of rural
society, the increasing source of pollution and the similarity in
environmental conditions in both areas due to close proximity
of each other in the crowded Nile Delta region.
In our study we found that there was highly signiﬁcant po-
sitive family history of atopic manifestations among asthmatic
groups than control group. This was in accordance with a
study done by Al Senaidy (2009). He found a signiﬁcant in-
crease in positive family history of atopy among cases than
control groups (p=<0.01) [18]. Also Castro and colleagues
(2004) stated that family history of asthma or atopy is one
of the early childhood risk factors for persistent asthma [17].
In the present study we found that there was highly signif-
icant positive increase in the presence of other atopic manifes-
tations among asthmatic children than controls. This was in
agreement with studies done by Lemanske and Busse (2003)
who reported that atopy is the strongest identiﬁable predispos-
ing factor for the development of asthma [19]. Approximately
75–80 percent of children with asthma have signiﬁcant allergies
[20].
In our study we found that there was highly signiﬁcant po-
sitive history of passive smoking in asthmatic children than
controls. Tobacco smoking is associated with accelerated de-
cline of lung function in people with asthma, increases asthma
severity and may render patients less responsive to treatmentTable 6 Serum L-carnitine levels in group I and severity of the asth
Variable Groups Mean ±
Serum L-carnitine levels (lmol/L) Mild 38.13 ±
Moderate 36.71 ±with inhaled and systemic glucocorticosteroids [21], and re-
duces the likelihood of asthma being controlled [22].
In our study, serum L-carnitine levels were signiﬁcantly low-
er in the asthmatics presented with acute attack than those
with stable asthma (p value = 0.001) and the controls (p va-
lue = 0.001). However, asthmatic children with a stable course
and the control group showed no signiﬁcant difference in car-
nitine levels (p value = 0.618).
This study also revealed that there was no signiﬁcant differ-
ence in serum L-carnitine levels in asthmatics with mild attack
and moderate asthmatic attack (p value = 0.692).
A signiﬁcant decrease in serum L-carnitine levels in asth-
matics with acute attack and 3 weeks after (p value = 0.001)
was found. These ﬁndings were in agreement with the results
of Asilsoy and Coworkers, who found that carnitine levels were
decreased during exacerbation of asthma and shortly thereaf-
ter in children with moderate asthma. They attributed the de-
crease of serum carnitine levels during the asthmatic attacks to
the decrease in lung surfactant (during attack) and the use of
body stores to replenish it (after attack) [23].
Also Al-Biltagi & Colleagues, reported that total and free
carnitine serum levels were signiﬁcantly lower in children with
moderate persistent asthma than in the control [24].
In the animal model, Uzuner & Researchers studied the ef-
fect of L-carnitine supplementation in mice with laboratory-in-matic attack.
SD Range Student’s t test P value
9.54 24–94 0.40 0.692 NS
9.76 23–70
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improved oxygen saturation and decreased urine leukotriene
E4 and inﬂammation in the lung tissues in the studied animals
[25].
Carnitine deﬁciency leads to toxic accumulation of long-
chain fatty acids in the cytoplasm and of acyl CoA in the mito-
chondria. The accumulated saturated and monounsaturated
fats may have different effects on airway inﬂammation [26].
Moreover, serum free carnitine levels were reported to be
decreased in children with recurrent pulmonary infections [27].
Respiratory viral infections are important triggers of asth-
ma attacks [28]. So children with low serum carnitine level
may have recurrent viral respiratory tract infections and hence
are more susceptible to develop asthma.
Kavukc¸u and Researchers showed that carnitine can im-
prove exercise tolerance and inspiratory muscle strength in
COPD patients as well as reduce lactate production and in-
crease rate of lactate removal [29].
It seems that carnitine supplementation restores body L-car-
nitine after its consumption in the synthesis of pulmonary sur-
factant via its hydrolysis by phospholipase A2 during acute
asthma attacks, especially the more severe ones [30].
Many studies stated that the surfactants of the asthmatic
lungs are functionally impaired. The main mechanism of this
impairment was thought to be due to the inﬂux of inhibitory
proteins into the airways, although changes in surfactant com-
position may occur. So L-carnitine supplementation improves
the synthesis and the functions of lung surfactants [31].
Kurz & Colleagues proved the beneﬁcial role of L-carnitine
intake by pregnant women in decreasing the incidence of respi-
ratory distress syndrome and even the mortality in premature
newborns. They attributed these effects to the physiological ac-
tion of L-carnitine in surfactant synthesis activation [32].
In this study there was a signiﬁcant positive correlation be-
tween L-carnitine and PEFR in groups Ia, Ib and II.
Leukotrienes are among the mediators of inﬂammation in
asthma and have a strong bronchoconstrictive effect. They
play an important role in airway eosinophilic inﬂammation,
leukocyte trafﬁcking, airway mucus secretion, airway edema,
collagen synthesis, and airway remodeling in asthmatic pa-
tients. It has been reported that L-carnitine inhibits leukotriene
synthesis by inactivation of lipoxygenase pathway and by
altering the ratio of essential fatty acids [33].
Borghi-silva & Coworkers demonstrated that L-carnitine
was able to prevent bronchospasm and improve the obstruc-
tive ﬁndings in PFT (pulmonary function tests) in children
undergoing chronic hemodialysis [7].
During asthma exacerbations inﬂammatory cells release
phospholipase A2 into the airway, which hydrolyzes phospha-
tidylcholine, the principal component of surfactant [34]. Thus,
the low level of serum carnitine in our asthmatic children dur-
ing or shortly after (3 weeks in this study) asthmatic attack
might be attributed to decreased lung surfactant (during at-
tack) and the use of body stores to replenish it (after attack).
Reestablishment of the baseline levels takes longer time
than 3 weeks. This may be an important factor for the speciﬁc-
ity of low levels of carnitine to indicate either an acute attack
or recent one, even in clinically improved patients. From our
results, it was noticed that PEFR correlates with serum carni-
tine at the time of acute asthmatic attack and 3 weeks later.
This may be explained on the basis of association of low levels
of carnitine and airway obstruction.In our study, the time interval of 3 weeks was not enough to
detect signiﬁcant changes regarding either PEFR or L-carnitine
levels in the same patient. Thus, it is recommended to make
further studies with extended time of testing to detect the per-
iod needed for return of L-carnitine to its normal levels.
The beneﬁcial effect of L-carnitine in asthmatic children
may be due to different mechanisms. It may be due to its anti-
microbial effect, muscle strength effects, enhancing surfactant
synthesis, antileukotriene activity, or through antagonizing
the harmful effects of fat on the respiratory tract, and bron-
chodilator effect (6-26-29-31-33).
Conclusion and recommendation
According to our study, it could be concluded that L-carnitine
decrease is linked to the occurrence of attack of bronchial asth-
ma, and correlated with PEFR. Accordingly, it is recom-
mended to make further studies to link out if there is a
beneﬁcial role of carnitine intake in the prophylaxis and treat-
ment of attacks of bronchial asthma. The recommended stud-
ies should search for the most suitable dose & side effects of
carnitine as a potential pharmaceutical agent.
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